Skip to main content

Living with Kidney Disease

Our research focuses on understanding the biology of kidney injury, as well as finding treatments and strategies. This in turn delays the decline of kidney function and decreases the risk of heart attacks and strokes in patients living with kidney disease. Diet, medications, and new blood tests are investigated to come up with the best strategy to help patients manage their kidney disease.

Publications and Presentations


  1. Anders HJ, Rovin B, Jayne D, Brunetta P, Coppo R, Davidson A, Devarapu SK, de Zeeuw D, Duffield J, Eulberg D, Fierro A. (2016). ISN Nexus 2016 Symposia: translational immunology in kidney disease—the berlin roadmap. Kidney International Reports. Nov 30;1(4):327-39.
  2. Dienemann T, Fujii N, Orlandi P, Nessel L, Furth SL, Hoy WE, Matsuo S, Mayer G, Methven S, Schaefer F, Schaeffner ES, Sola L, Stengel B, Wanner C, Zhang LX, Levin A, Eckardt KU, Feldman HI. (2016). International network of chronic kidney disease cohort lestudies (iNET-CKD): a global network of chronic kidney disease cohorts. Bmc Nephrology.17:9.
  3. Hassan HIC, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. (2016). Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney-disease and mortality. Kidney International. 90(4):897-904.
  4. Kadatz MJ, Lee ES, Levin A. (2016). Predicting progression in CKD: Perspectives and precautions. American journal of kidney diseases. 67(5):779-786.
  5. Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, Holmes DT, Madore F, Clase CM, Rigatto C, Levin A, Can PI. (2016). Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney international. 89(5):1144-1152.
  6. Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DMJ, Nally J, Rothenbacher D, Stengel B, Iseki K, Matsushita K, Levey AS, Consortium CKDP. (2016). Past decline bersus current eGFR and subsequent ESRD risk. Journal of the American Society of Nephrology.27(8):2447-2455.
  7. Langsford D, Tang M, Djurdjev O, Er L, Levin A. (2016). The variability of estimated glomerular filtration rate decline in alport syndrome. Can J Kidney Health Dis. 3:2054358116679129.
  8. Levin A, Harris D, Remuzzi G, Horton R, Berman P. (2016). The lancet kidney campaign: an opportunity for partnerships. Lancet. 387(10023):1038-1039.
  9. Levin A, Lan JH.(2016).Cystatin C and cardiovascular disease causality, association, and clinical implications of knowing the difference. Journal of the American College of Cardiology. 68(9):946-948.
  10. Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, Wanner C, Kasiske BL, Wheeler DC, Groop PH, Conf P. (2016). Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International. 90(6):1175-1183.
  11. Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellstrom B, Jiang LX, Kasiske BL, Krane V, Levin A, Walker R, Wanner C, Wheeler DC, Landray MJ, Baigent C, Emberson J, Grp SC. (2016).Smoking and adverse outcomes in patients With CKD: The study of heart and renal protection (SHARP). American Journal of Kidney Diseases. 68(3):371-380.

  1. Bello, AK, Levin, A, Manns, BJ, Feehally, J, Drueke, T, Faruque, L, Hemmelgarn, BR, Kernahan, C, Mann, J, Klarenbach, S, Remuzzi, G, Tonelli, M, Kidney Health Life, I. (2015). Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. American Journal of Kidney Diseases, 65(1), 15-25.
  2. Chiu, HH, Tangri, N, Djurdjev, O, Barrett, BJ, Hemmelgarn, BR, Madore, F, Rigatto, C, Muirhead, N, Sood, MM, Clase, CM, Levin, A. (2015). Perceptions of prognostic risks in chronic kidney disease: a national survey. Can J Kidney Health Dis, 2, 53.
  3. Davison, SN, Levin, A, Moss, AH, Jha, V, Brown, EA, Brennan, F, Murtagh, FEM, Naicker, S, Germain, MJ, O'Donoghue, DJ, Morton, RL, Obrador, GT. (2015). Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney International. 88(3), 447-459.
  4. Graziani MS, Plebani M. (2015). The standardization of the urine albumin assays: no longer deferrable. Clinical Chemistry and Laboratory Medicine (CCLM). 53(11):1657-9.
  5. Iansavichus, AV, Hildebrand, AM, Haynes, RB, Wilczynski, NL, Levin, A, Hemmelgarn, BR, Tu, K, Nesrallah, GE, Nash, DM, Garg, AX. (2015). High-Performance Information Search Filters for CKD Content in PubMed, Ovid MEDLINE, and EMBASE. American Journal of Kidney Diseases, 65(1), 26-32.
  6. Levin, A, Wheeler, DC. (2015). A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking. Seminars in Dialysis, 28(6), 654-656.
  1. Abraham AG, Mak RH, Mitsnefes M, White C, Moxey-Mims M, Warady B, Furth SL. (2014). Protein energy wasting in children with chronic kidney disease. Pediatric Nephrology. 29(7):1231-8.
  2. Aydede  SK, Komenda P, Djurdjev O, Levin A. (2014). Chronic Kidney Disease and support provided by home care services: a systematic review. BMC Nephrology. 15 (1), p 118
  3. Coresh, J, Turin, TC, Matsushita, K, Sang, Y, Ballew, SH, Appel, LJ, Arima, H, Chadban, SJ, Cirillo, M, Djurdjev, O, Green, JA, Heine, GH, Inker, LA, Irie, F, Ishani, A, Ix, JH, Kovesdy, CP, Marks, A, Ohkubo, T, Shalev, V, Shankar, A, Wen, CP, de Jong, PE, Iseki, K, Stengel, B, Gansevoort, RT, Levey, AS, CKD Prognostic Consortium. (2014). Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. Jama-Journal of the American Medical Association. 311(24), 2518-2531.
  4. Coulter-Mackie MB, White CT, Lange D, et al. Primary Hyperoxaluria Type 1. 2002 Jun 19 [Updated 2014 Jul 17]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from:
  5. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrinton WG, Baigent C, Landray MJ, for the SHARP Collaborative Group. (2014). Effects of lowering LDL cholesterol on progression of kidney disease. Journal of the American Society of Nephrology. 2014 May 1:ASN-2013090965.
  6. Haynes R, Staplin N, Emberson J, Herrington WG, Tomson C, Agodoa L, Tesar V, Levin A, Lewis D, Reith C, Baigent C, Landray MJ, on behalf of the SHARP Collaborative Group. (2014). Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases. 64(1):40-8.
  7. Levin A, Remuzzi G. (2014). Clinical trials: ISN-ACCTS: global initiatives to improve clinical research. Nature Reviews Nephrology. 2014 Aug 1;10(8):426-7.
  8. Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Clase C, Tang M, Djurdjev O, and on behalf of the CanPREDDICT Investigators. (2014). Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort”, NDT, May 2014; 29(5), pp 1035-45
  9. Levin A, Stevens PE. (2014). Summary of KDIGO 2012 CKD Guideline:  behind the scenes, need for guidance, and a framework for moving forward. KI. 85(1), pp 49-61
  10. Levin A. (2014). Commentary on “Kidney disease guideline profusion and confusion:  unintended consequences of different perspectives and definitions”, AJKD, May 2014; Vol 63, Issue 5, pp 749-52
  11. Levin, A, Perry, T, De Zoysa, P, Sigrist, MK, Humphries, K, Tang, M, Djurdjev, O. (2014). A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients. Bmc Cardiovascular Disorders, 14.
  12. Levin, A, Remuzzi, G. (2014). CLINICAL TRIALS ISN-ACCTS: global initiatives to improve clinical research. Nature Reviews Nephrology, 10(8), 426-427.
  13. Levin, A, Stevens, PE, Coresh, J, Levey, A. (2014). Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease. Annals of Internal Medicine, 161(1), 81-82.
  14. Lopez AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, Rehm J, Volkow ND, Koob G, Ferri CP. (2014). Remembering the forgotten non-communicable diseases. BMC medicine. 12(1):200.
  15. Lopez, AD, Williams, TN, Levin, A, Tonelli, M, Singh, JA, Burney, PGJ, Rehm, J, Volkow, ND, Koob, G, Ferri, CP. (2014). Remembering the forgotten non-communicable diseases. Bmc Medicine, 12.
  16. Okamura DM, Bahrami NM, Ren S, Pasichnyk K, Williams JM, Gangoiti JA, Lopez-Guisa JM, Yamaguchi I, Barshop BA, Duffield JS, Eddy AA. (2014).Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD. JASN 25:43-54, 2014. PMID: 24009239 
  17. Samuel S, Scott S, Morgan C, Dart A, Mammen C, Parekh R, Nettel-Aguirre A, Eddy A, Flynn R, Pinsk M, Wade, A, Arora S, Benoit G, Bitxan M, Erickson R, Feber J, Geier P, Giradin C, Grisaru S, Tee J, Kemp K and Zapitelli, M. (2014). The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: overview of design and methods. Canadian Journal of Kidney Health and Disease. 1:17
  18. Sud M, Tangri N, Levin A, Pintilie M, Levey A, Naimark D. (2014). CKD stage at nephrology referral and factors influencing the risks of ESRD and death. AJKD. 63(6): 928-36 
  19. Wen, CP, Matsushita, K, Coresh, J, Iseki, K, Islam, M, Katz, R, McClellan, W, Peralta, CA, Wang, HY, de Zeeuw, D, Astor, BC, Gansevoort, RT, Levey, AS, Levin, A, Chronic Kidney Dis, P. (2014). Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney International, 86(4), 819-827.
  1. Burger, D, Levin, A. (2013). 'Shedding' light on mechanisms of hyperphosphatemic vascular dysfunction. Kidney International. 83(2), 187-189.
  2. Coresh J, Levey AS, Levin A, Stevens P. (2013). A stable definition of chronic kidney disease improves knowledge and patient care. BMJ. 347.
  3. Eddy AA. (2013). The origin of kidney scar-forming myofibroblasts. Nat Med. 19:964-966. 
  4. Hiatt MJ, Matsell DG. Urinary tract obstruction in the mouse- The kinetics of distal nephron injury. Laboratory Investigation. 93:1012-23.
  5. Hizo-Abes P, Clark WF, Sontrop JM, Young A, Huang A, Thiessen-Philbrook H, Austin PC, Garg AX; Walkerton Health Study Investigators. Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. Canadian Medical Association Journal. 185:E70-7.
  6. Mammen C, Matsell DG, Lemley KV. The importance of clinical pathways and protocols in pediatric nephrology. (2014). Pediatric Nephrology. 29(10):1903-14.
  7. Levey, AS, Levin, A, Kellum, JA. (2013). Definition and Classification of Kidney Diseases. American Journal of Kidney Diseases, 61(5), 686-688.
  8. Levin, A, Lancashire, W, Fassett, RG. (2013). Targets, trends, excesses,  ,deficiencies: refocusing clinical investigation to improve patient outcomes. Kidney International, 83(6), 1001-1009.
  9. Levin A,  Lo C, Noel K, Djurdjev O, Amano EC. Activity-based funding model provides foundation for province-wide best practices in renal care. Healthcare Quarterly. 16(4):49-54.
  10. Levin, A, Perkovic, V. (2013). EPIDEMIOLOGY Global Burden of Disease Study 2010: implications for nephrology. Nature Reviews Nephrology, 9(4), 195-197.
  11. Levin A, Stevens PE, Bilous RW. (2013). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-50.
  12. Levin, A, Rigatto, C, Brendan, B, Madore, F, Muirhead, N, Holmes, D, Clase, CM, Tang, M, Djurdjev, O, Can, PI. (2013). Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). Bmc Nephrology, 14.
  13. Levin, A, Stevens, PE. (2013). Comments on. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease' Reply. Kidney International, 84(3), 623-623.
  14. Levin, A, Stevens, PE. (2014). Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney International. 85(1), 49-61.
  15. Mammen C, Matsell DG, Lemley KV. The importance of clinical pathways and protocols in pediatric nephrology. (2014). Pediatric Nephrology. 29(10):1903-14.
  16. Matsushita, K, Ballew, SH, Astor, BC, de Jong, PE, Gansevoort, RT, Hemmelgarn, BR, Levey, AS, Levin, A, Wen, CP, Woodward, M, Coresh, J, CKD Prognosis Consortium (2013). Cohort Profile: The Chronic Kidney Disease Prognosis Consortium. International Journal of Epidemiology, 42(6), 1660-1668.
  17. Nitsch, D, Grams, M, Sang, YY, Black, C, Cirillo, M, Djurdjev, O, Iseki, K, Jassal, SK, Kimm, H, Kronenberg, F, Oien, CM, Levey, AS, Levin, A, Woodward, M, Hemmelgarn, BR, CKD Prognosis Consortium. (2013). Associations of estimated glomerular filtration rate and albuminuria with mortality  ,renal failure by sex: a meta-analysis. Bmj-British Medical Journal, 346.
  18. Schachter ME, Romann A, Djurdev O, Levin A, Beaulieu M. (2013). The British Columbia Nephrologists' Access Study (BCNAS) -- a prospective, health services interventional study to develop waiting time benchmarks and reduce wait times for out-patient nephrology consultations. BMC Nephrol. 2013 Aug 29;14(1):182. [Epub ahead of print]
  19. Scherer, A, Gunther, OP, Balshaw, RF, Hollander, Z, Wilson-McManus, J, Ng, R, McMaster, R, McManus, BM, Keown, PA. (2013). Alteration of human blood cell transcriptome in uremia. Bmc Medical Genomics, 6.
  20. Sigrist, M, Tang, M, Beaulieu, M, Espino-Hernandez, G, Er, L, Djurdjev, O, Levin, A. (2013). Responsiveness of FGF-23  ,mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrology Dialysis Transplantation, (281), 161-169.
  21. Stevens, PE, Levin, A, Kidney Dis Improving, G. (2013). Evaluation  ,Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Annals of Internal Medicine, 158(11), 825-+. 
  1. Ajarmeh S, Er L, Brin G, Djurdjev O, Dionne JM. The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease. Pediatric Nephrology. 27:1921-1927, 2012.
  2. Atkinson MA, Pierce CB, Fadrowski JJ, Benador NM, White CT, Turman MA, Pan CG, Abraham AG, Warady BA, and Furth SL. Association between common iron store markers and hemoglobin in children with chronic kidney disease. Pediatric Nephrology (2012). 27(12):2275-83.
  3. Atkinson MA, White CT. Invited Review. Hepcidin in Anemia of Chronic Kidney Disease: Review for the Pediatric Nephrologist. Pediatric Nephrology (2012). 27(1):33-40.
  4. Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, White CT, Furth S, Warady BA, Mitsnefes M. Carotid intimal thickness in children with CKD: Results from the Chronic Kidney Disease in Children Cohort Study. Clinical Journal of the American Society of Nephrology (2012). 7(12):1930-1937.
  5. Burger D, Levin A. ‘Shedding’light on mechanisms of hyperphosphatemic vascular dysfunction. (2013).  Kidney international. 83(2):187-9.
  6. Chang AM, Ohse T, Krofft RD, Wu JS, Eddy AA, Pippin JW, Shankland SJ. Albumin-induced apoptosis of glomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2. Nephrol Dial Transplant. 2012 Apr;27(4):1330-43.
  7. Collin K, Dionne JM, Er L, Lou K, White CT. Pharmaceutical cost distribution in childhood chronic kidney disease. Pediatric Nephrology. 27:1531-1539.
  8. Dionne J, Lou K, Er L, Collin K, White CT. Pharmaceutical Cost of Childhood Chronic Kidney Disease. Pediatric Nephrology, 27(2012); 1531-1539.
  9. Dionne JM, Flynn JT. Hypertension in the neonate. NeoReviews. 13(7):e401-409, 2012. 
  10. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: Diagnosis, management and outcome. Pediatric Nephrology. 27:17-32, 2012. 
  11. Eddy AA, L pez-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol. 2012 Aug;27(8):1233-47.
  12. Fairhead T, Hendren D, Tinckam K, Rose C, Sherlock C, Shi L, Crowcroft N, Landsberg D, Knoll G, Gill J, Kumar D. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transplant Infectious Disease. October 2012.
  13. Fox DA, Matsell DG, Hursh BE, Mammen C. A rare cause of hypertension in a healthy two-year-old female: Questions. Pediatric Nephrology. 27:2053-54.
  14. Hallan S, Matsushita K, Sang Y, Mahmoodi B, Black C, Ishani A, Levin A, et al. Age and Association of Kidney Measures with Mortality and End-Stage Renal Disease. JAMA Dec 2012; 308(22):2349-60.
  15. Hanko J, Romann A, Taylor P, Copland M, and Beaulieu M. Optimizing AVF creation prior to dialysis start: the role of predialysis renal replacement therapy choices. Nephrology, Dialysis and Transplantation September 2012.
  16. Hemmelgarn BR, Manns BJ, Straus S, Naugler C, Holroyd-Leduc J, Braun TC, Levin A, Klarenbach S, Lee PF, Hafez K, Schwartz D. (2012). Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. Journal of nephrology. 25(6):933.
  17. Heran MKS, Bippan SS, White C. Case Report: Renal hyperperfusion injury resulting in transient proteinuria post renal artery angioplasty for fibromuscular dysplasia. Pediatric Radiology Pediatric Radiology (April 2012). 42(4):491-4.
  18. Levin A, Locatelli F. (2012). The new research agenda and public health interface: a framework for improving care. Nephrology Dialysis Transplantation July 2012.  
  19. Levin A, Djurdjev O. On Being Better Kidney Doctors: Understanding Trajectories, Probabilities, Predictability, and People. Am J Kidney Dis. 2012;59(4):475-477, April 2012.
  20. Levin A, Le Barbier M, Er L, Andress D, Sigrist M, Djurdjev O. Incident isolated 1,25 vitamin D deficiency is more common in CKD patients than isolated 25 vitamin D deficiency over 12 months. Journal of Nephrology Mar 2012; 25(2):204-10.
  21. Levin A. (2012). Dr. Levin Replies. Letter Section, BCMJ, Apr 2012; 54(3):125.  
  22. Levin A. (2012). Ongoing gaps in CKD and CVD care: re-evaluating strategies for knowledge dissemination. Editorial Comment, NDT Apr 2012; 27(4):1282-4.  
  23. Levin A. (2012). Year in Review 2011 - Progression, prediction, populations and possibilities. Nature Reviews Nephrology, Feb 2012; 8(2)70-2.  
  24. Locatelli F, Levin A. Introduction and context: the past, present and future of CKD research. NDT advance published July 2012.
  25. Lopez-Guisa JM, Cai X, Collins SJ, Yamaguchi I, Okamura DM, Bugge TH, Isacke CM, Emson CL, Turner SM, Shankland SJ, Eddy AA. Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol. 2012 Feb;23(2):236-51.
  26. Mammen C, Al Abbas A, Skippen P, Nadel H, Levine D, Collet JP, Matsell DG. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: A prospective cohort study.American Journal of Kidney Disease 59:523-30.
  27. Matsushita K, Ballew S, Astor B, de Jong P, Gansevoort R, Hemmelgarn B, Levey A, Levin A, Wen C-P, Woodward M, Coresh J, et al. Cohort profile: The Chronic Kidney Disease Prognosis Consortium. Published online, International Journal of Epidemiology, Dec 2012.
  28. Rajan T, Levin A. A quality improvement project to improve the management of hyperkalemia in hospitalized patients. BCMJ Jan/Feb 2012; 54(1):29-33.
  29. Sigrist M, Tang M, Beaulieu M, Espino-Hernandez G, Er L, Djurdjev O, Levin A. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.Nephrology, Dialysis and Transplantation September 2012.
  30. Walsh E, Wald R, Levin A, Bouchard J et al. Timing the initiation of renal replacement therapy for acute kidney injury in Canadian intensive care units: a multicenter observational study. Canadian Journal of Anaesthesia June 2012; 59(9):861-70.
  31. Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force. Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012 Oct;7(10):1664-72.
  32. Wilson AC, Schneider MF, Cox C, Greenbaum LA, Saland J, White CT, Furth S, Warady B, Mitsnefes M. Prevalence and Correlates of Multiple Traditional Cardiovascular Risk Factors in Children with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 2012. 6:2759-65.
  33. Yamaguchi I, Tchao BN, Burger ML, Yamada M, Hyodo T, Giampietro C, Eddy AA. Vascular endothelial cadherin modulates renal interstitial fibrosis. Nephron Exp Nephrol. 2012;120(1):e20-31.
  34. Zakrzewski P, MacKenzie P, Tsai G, Warner S, Levin A, Mikelberg F. Does an association exist between Pseudoexfoliation Syndrome and Chronic Kidney Disease. Journal of Glaucoma Oct/Nov 2012; 21(8):562-6.
  1. Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. The Lancet. 2011 Jun; 377(9784):2151-2248.
  2. Baldwin C, Farah M, Leung M, Taylor P, Werb R, Kiaii M, Levin A. Multi-intervention management of Calciphylaxis: a report of 7 cases. AJKD. 2011 Dec; 58(6):988-91.
  3. Barrett B, Garg A, Goeree R, Levin A, Molzahn A, Rigatto C, Singer J, Soltys G, Soroka S, Ayers D, Parfrey P. A nurse-coordinated model of care versus usual care for Stage ¾ Chronic Kidney Disease in the community: a randomized controlled trial. CJASN. 2011 Jun; 6:1241-7.
  4. Coulter-Mackie MB, White CT, Hurley RM, Chew BH, Lange D. Primary Hyperoxaluria Type 1 (November 2011) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2010. Available at
  5. Eddy AA. Scraping fibrosis: UMODulating renal fibrosis. Nat Med. 2011 May;17(5):553-5.
  6. Eddy AA. The TGF-? route to renal fibrosis is not linear: the miR-21 viaduct. J Am Soc Nephrol. 2011 Sep;22(9):1573-5.
  7. Farah M, Crawford RI, Levin A, Chan-Yan C. Calciphylaxis in the current era: emerging ‘ironic’ features? NDT. 2011 Jan; 26(1):191-5.
  8. Hopkins RB, Garg AX, Levin A, Molzahn, A, Rigatto C, Singer J, Soltys G, Soroka S, Parfrey PS, Barrett BJ, Goeree R. Cost-effectiveness analysis of a randomized trial comparing care models for chronic kidney disease. Published online, CJASN. 2011 Jun; 6(6):1248-57.
  9. Isakova T, Gutierrez O, Patel N, Andress D, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. Journal of Renal Nutrition. 2011 Jul; 21(4):295-302.
  10. Koh JC, Koo W. Chinese nutrition educational materials for renal patients: A 2010 update. Journal of Renal Nutrition (online). 2011 Mar; 21(2):e1-e4.
  11. Lebner AC, Beard KM, Soroka SD, Cournoyer SH, Da Roza GA, Geary DF, Mendelssohn DC. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada. Nephrology Dialysis Transplantation.2011; 26:156-163.
  12. Levin A, Beaulieu MC. Trials and Tribulations of New Agents, Novel Biomarkers, and Retarding Renal Progression. Published online, JASN. 2011 Jun; 22(6):992-3.
  13. Levin A, Stevens P. Early detection of CKD: benefits, limitations and prognosis.Nature Reviews Nephrology. 2011 Aug; 7:446-57.
  14. Lopez-Guisa JM, Rassa AC, Cai X, Collins SJ, Eddy AA. Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease. Am J Physiol Renal Physiol. 2011 May; 300(5):F1244-54.
  15. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu F-T, Eddy AA. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol. 300:F245-253.
  16. Prestidge C, Chilvers MA, Davidson AGF, Cho E, McMahon V, White CT. Renal function in pediatric cystic fibrosis patients in the first decade of life. Pediatric Nephrology. 2011; 26(4):605-612.
  17. Rajan T, Barbour S, White C, Levin A. Low birth weight and nephron mass as a role in the progression of chronic kidney disease: a case report on identical twins with Alport Disease. NDT. 2011 Dec; 26(12):4136-9.
  18. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive model for progression of Chronic Kidney Disease to kidney failure. JAMA. 2011 Apr; 305(15):1553-9.
  19. Tanna GV, Sood MM, Schiff J, Schwartz D, Naimark DM. Do E-mail Alerts of New Research Increase Knowledge Translation? A "Nephrology Now" Randomized Control Trial. Acad Med. 2011 Jan; 86(1):132-138. 
  20. Weber C, Beaulieu M, Djurdjev O, Er L, Taylor P, Ignaszewski A, Burnett S, Levin A. (2011). Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease–cardiovascular disease–diabetes. Nephrology Dialysis Transplantation. 2011 Jun 30:gfr292.
  21. Weber C, Bennett M, Er L, Bennett MT, Levin A. Urinary NGAL levels before and after coronary angiography: a complex story. NDT. 2011 Oct; 26(10):3207-11.
  22. Zhang G, Thomas AL, Marshall AL, Kernan KA, Su Y, Zheng Y, Takano J, Saido TC, Eddy AA. Nicotinic acetylcholine receptor ?1 promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy. Lab Invest.2011 Jan;91(1):106-23.
  1. Barbour SJ, Er L, Djurdjev O, Karim MA, Levin A. (2010). Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients. Nephrology, Dialysis, Transplantation. 25(11):3663-72.
  2. Barbour SJ, Schachter M, Er L, Djurdjev O, Levin A. (2010). A systematic review of ethnic differences in the rate of renal progression in CKD patients.Nephrology, Dialysis, Transplantation. Aug 2010; 25(8):2422-30.
  3. Hiatt MJ, Ivanova L, Toran N, Tarantal AF, Matsell DG. (2010). Remodeling of the fetal collecting duct epithelium. The American Journal of Pathology. 176(2):630-637. 
  4. Ivanova L, Hiatt MJ, Yoder MC, Tarantal AF, Matsell DG. (2010). Ontogeny of CD24 in the human kidney. Kidney International. 77(12):1123-1131. 
  5. Lafrance JP, Djurdjev O, Levin A. (2010). Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. Nephrology Dialysis Transplantation. 25(7):2203-2209.
  6. Lebner AC, Beard KM, Soroka SD, Cournoyer SH, Da Roza GA, Geary DF, Mendelssohn DC. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada. NDT Advance Access, e-pub published July 28, 2010. 
  7. Levin A. (2010). Health care reform, US and Canada: Musings as to myths and caveats. Renal and Urology News. June 2010.
  8. Levin A, Beaulieu M. (2010). TREAT: Implications for guideline updates and clinical care, commentary on Pfeffer MA, Burdmann EA, Chen CY, et al; for the TREAT Investigators. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEJM, 361(21):2019-2032. American Journal of Kidney Diseases. 55(6):984-987.
  9. Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Aukema HM. The benefit of soy protein diet in experimental polycystic kidney disease is preserved after isoflavone depletion. Exp Biol Med. 235:1315–1320, 2010.
  10. Warnock DG, Remuzzi G, Brenner BM, Levin A, Wanner C. (2010). Introduction to focus on Fabry nephropathy: Biomarkers, progression, and disease severity. Clinical Journal of the American Society of Nephrology. 5(2):359.  


  1. Global Perspectives on CKD
    Speaker: Dr. Adeera Levin
  1. Improving Access to Specialist Care in Rural Communities 
    Team: Brian Forzley, Ella Monro, Lisa Needoba (Interior Health)
  1. Bioimpedance Assessment of Volume Status in Referred Patients with Chronic Kidney Disease: Baseline Data from Bio-CanPREDDICT
    Organzations: McMaster University; St. Paul's Hospital; University of British Columbia; BC Renal Agency
    Team: Mohammed Tawhari, Azim Gangji, Trevor Wilkieson, Mila Tang, Adeera Levin, Catherine Clase, Ognjenka Djurdjev
  2. Challenges and Opportunities for Effective Chronic Kidney Disease Care Delivery: A Synthesis of Health Systems and Policies from 19 Countries
    Organizations:University of Alberta; University of British Columbia; University of Calgary; Université de Picardie; Mario Negri Institute.
    Team: Aminu K. Bello, Adeera Levin, Braden J. Manns, Tilman B. Drueke, Brenda Hemmelgarn, Scott Klarenbach, Giuseppe Remuzzi, Marcello Tonelli
  3. Development, Implementation and Evaluation of a Web-Based Clinical Pathway for Chronic Kidney Disease in Primary Care
    Organizations: University of Calgary; University of Alberta; University of British Columbia; Alberta Health Services
    Team: Maoliosa Donald, Braden Manns, Marcello Tonelli, Kailash Jindal, Nairne Scott-Douglas, Adeera Levin, Tom Noseworthy, Richard Lewanczuk
  4. Different Biomarker Profiles Identify Chronic Kidney Disease Patients of Different Etiologies at the Highest Risk of Mortality before Progression to Dialysis Dependence
    Organizations: University of British Columbia; BC Renal Agency
    Team: David Langsford, Ognjenka Djurdjev, Mila Tang, Adeera Levin.
  5. eGFR Level and Its Past Trajectory for Risk of Progression to End-Stage Renal Disease: Meta-Analysis of 22 Cohorts in the CKD Prognosis Consortium
    Organization: CKD Prognosis Consortium
    Team:Csaba P. Kovesdy, Josef Coresh, Shoshana Ballew, Mark Woodward, David M. Naimark, Joseph V. Nally, Adeera Levin, Dietrich Rothenbacher, Benedicte Stengel, Kunitoshi Iseki, Kunihiro Matsushita, Andrew S. Levey
  6. Evolving Care Systems - A Co-location Model for Change
    Organization: Providence Health Care
    Team: Amable Cruz; Laddie Frank; Camille Rozon; Stan Marchuk; Michele Trask
  7. Infection Is a Risk Factor for Faster Progression to Renal Replacement Therapy and Death in Chronic Kidney Disease
    Organizations: St. Paul's Hopital; University of New South Wales; BCPRA; University of British Columbia
    Team: Hicham I. Cheikh Hassan, Mila Tang, Ognjenka Djurdjev, Adeera Levin
  8. Leukocyte Chemotactic Factor 2 (LECT2) Amyloidosis in First Nations People in British Columbia, Canada: A Case Series
    Organizations: Monash University; St Paul's Hospital.
    Team: Holly L. Hutton, Mari DeMarco, Alexander Magil, Paul Taylor
  9. Newer Biomarkers Improve Prediction of Cardiovascular Events in CKD Patients - CanPREDDICT Study Outcomes
    Organizations: University of British Columbia; University of Manitoba; Université de Montréal; Memorial University of Newfoundland; Western University; St. Paul's Hospital; McMaster University; BC Renal Agency
    Team: Adeera Levin, Claudio Rigatto, Francois Madore, Brendan J. Barrett, Norman Muirhead, Daniel Holmes, Catherine Clase, Mila Tang, Ognjenka 
  10. Prognostic Value of Prediction Equations and "Surprise Question" in CKD Patients in Identifying Need for Renal Replacement - CanPREDDICT Study"
    Organizations: University of Manitoba; Université de Montréal; Memorial University of Newfoundland; University of Western Ontario; St. Paul's Hospital; McMaster University; Provincial Health Services Authority; BC Renal Agency; University of British Columbia
    Team: N. Tangri, Claudio Rigatto, F. Madore, B. Barrett, N. Muirhead, D.H. Holmes, C.M. Clase, Mila Tang, Ognjenka Djurdjev, Adeera Levin, on behalf of the CanPREDDICT investigators
  11. Small Returns for Big Investment: CKD-MBD Therapy from 2005 to 2013
    Organizations: University of British Columbia; BC Provincial Renal Agency
    Team:  Katrina Chau, Lee Er, Ognjenka Djurdjev, Adeera Levin.
  12. The Canadian Society of Nephrology Methods in Developing and Adapting Clinical Practice Guidelines: A review
    Organizations: St. Michael's Hospital; University of British Columbia; University of Ottawa; McGill University; Humber River Hospital; The Ottawa Hospital; Hôpital du Sacré-Coeur de Montréal; University of Saskatchewan; Western University; University of Alberta; University of Calgary
    Team: Phil McFarlane, Adeera Levin, Ayub Akbari, Bethany Foster, Deb Zimmerman, Gihad Nesrallah, Greg Knoll, Jean-Philippe Rioux, Jim Barton, Marcel Ruzicka, Norman Muirhead, Louise Moist, Neesh Pannu
  13. Urinary ACR and PCR are Prognostically Equivalent: Implications for Clinicians and Laboratories
    Organizations: University of Manitoba; University of British Columbia; McMaster University; Memorial University of Newfoundland; Université de Montréal; University of Western Ontario; St. Paul's Hospital; BC Renal Agency
    Team: Claudio Rigatto, Adeera Levin, Catherine Clase, Brendan Barrett, François Madore, Norman Muirhead, Daniel Holmes, Mila Tang, Navdeep Tangri, Ognjenka Djurdjev
  1. Change in GFR and subsequent mortality: meta-analysis of 32 cohorts in the CKD prognosis consortium
    Team:Tanvir Chowdhury Turin; Kunihiro Matsushita; Josef Coresh; Hisatomi Arima; Steven J. Chadban; Massimo Cirillo; Ognjenka Djurdjev; Jamie Alton Green; Fujiko Irie; Joachim H. Ix; Csaba P. Kovesdy; Takayoshi Ohkubo; Chi Pang Wen; Paul E. de Jong; Kunitoshi Iseki; Benedicte Stengel; Ron T. Gansevoort; CKD Prognosis Consortium 
  2. Newer biomarkers improve prediction of death in CKD patients – CanPREDDICT study outcomes
    Organizations: University of British Columbia; BC Renal Agency; University of Manitoba; Université de Montréal; Memorial University of Newfoundland; Western University; University of Miami Miller School of Medicine
    Team: Adeera Levin; Ognjenka Djurdjev; Claudio Rigatto; Francois Madore; Brendan J. Barrett; Norman Muirhead; Myles S. Wolf
  3. Newer biomarkers slightly improve prediction of progression to renal replacement therapy in CKD patients – CanPREDDICT study outcomes
    Organization: University of British Columbia; BC Renal Agency; University of Manitoba; Université de Montréal; Memorial University of Newfoundland; Western University; University of Miami Miller School of Medicine
    Team:  Adeera Levin; Ognjenka Djurdjev; Claudio Rigatto; Francois Madore; Brendan J. Barrett; Norman Muirhead; Myles S. Wolf
  4. Perceptions of risks in chronic kidney disease among patients, clinicians and administrators
    Organizations: PHCRI; University of Manitoba; Provincial Health Services Authority; BC Provincial Renal Agency; Memorial University of Newfoundland; U of C; Université de Montréal; Western University; MU; University of British Columbia
    Team: Helen Chiu; Navdeep Tangri; Ognjenka Djurdjev; Brendan J. Barrett; Brenda Hemmelgarn; Francois Madore; Claudio Rigatto; Norman Muirhead; Manish M. Sood; Catherine M. Clase; Adeera Levin
  5. Urinary albumin:creatinine and protein:creatinine are prognostically equivalent for CKD progression: results from CanPREDDICT
    Organizations: University of Manitoba; University of British Columbia; McMaster University; Université de Montréal; Memorial University of Newfoundland; London Health Science Centre; St. Paul's Hospital; BC Provincial Renal Agency
    Team: Claudio Rigatto; Adeera Levin; Catherine M. Clase; Brendan J. Barrett; Francois Madore; Norman Muirhead; Navdeep Tangri; Mila Tang; Ognjenka Djurdjev
  6. Validation of the kidney failure risk equation in an international consortium
    Team: Navdeep Tangri; Andrew S. Levey; M. Grams; Josef Coresh; Brad C. Astor; Allan J. Collins; Ognjenka Djurdjev; Carolyn Raina Elley; Stein I. Hallan; Lesley Inker; Csaba P. Kovesdy; Florian Kronenberg; Hiddo Jan Lambers Heerspink; Angharad Marks; Sankar D. Navaneethan; Robert G. Nelson; Mark J. Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki; CKD Prognosis Consortium
  1. An overview of the BC patients with Chronic Kidney Disease registered from 2003 to 2007
    Organizations: BC Renal Agency and Division of Nephrology, University of British Columbia
    Team:  Adeera Levin, Gabriela Espino-Hernandez; Lee Er; Ognjenka Djurdjev; Monica Beaulieu
  2. Arteriovenous fistulas created before dialysis start – ongoing evaluation of preemptive AVF outcomes in British Columbia
    Organization: BC Renal Agency and Division of Nephrology, University of British Columbia
    Team: Monica Beaulieu, Alexandra Romann; Janet Williams; Mercedeh Kiaii


Tab Heading
Tab Heading
SOURCE: Living with Kidney Disease ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Renal Agency. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority